146: Therapeutic advantage of concurrent chemoradiotherapy with 55 Gy/20 fractions with cisplatinum and vinorelbine assessed by comparing control rates predicted by radio-biological (Biosuite) software and clinical results. (January 2015) - Maguire, J.; Uzan, J.; Kelly, V.